PPG Industries Inc. 10-Q Summary: Quarter Ended September 30, 1994
Business Context and Reporting Period
This Form 10-Q covers the three and nine months ended September 30, 1994, for PPG Industries, Inc., a global manufacturer of coatings, glass, and chemicals. The company operates through three primary segments: Coatings and Resins, Glass, and Chemicals. The reporting period reflects the impact of a two-for-one stock split executed in June 1994 and ongoing strategic divestitures, including the Biomedical Systems Division.
Key Financial Metrics
| Metric (Millions) | Q3 1994 | Q3 1993 | 9M 1994 | 9M 1993 |
|---|---|---|---|---|
| Net Sales | $1,575.3 | $1,405.4 | $4,671.5 | $4,375.7 |
| Gross Profit | $613.2 | $520.5 | $1,809.7 | $1,611.0 |
| Gross Margin % | 38.9% | 37.0% | 38.7% | 36.8% |
| Net Income | $145.5 | $24.8 | $363.6 | $(31.7) |
| Earnings Per Share | $0.68 | $0.12 | $1.71 | $(0.15) |
| Cash from Operations (9M) | $503.0 | $467.8 | ||
| Capital Spending (9M) | $(224.0) | $(220.8) | ||
| Total Debt (Short + Long Term) | $1,068.4 | $1,129.1 | ||
| Cash and Equivalents | $165.7 | $111.9 | ||
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12.1% in Q3 and 6.8% for the nine-month period, driven by higher volumes across all segments and the acquisition of Akzo's European auto coatings business. This growth offset the loss of revenue from divested Biomedical and glass operations.
- Profitability Surge: Net income for the nine months turned from a $31.7 million loss in 1993 to a $363.6 million profit in 1994. The 1993 loss was heavily impacted by a $363.2 million cumulative charge for accounting changes regarding postretirement benefits and $88.4 million in divestiture charges. The 1994 period benefited from the absence of these large one-time charges.
- Segment Performance: The Glass segment improved from a $31 million operating loss in Q3 1993 to a $74 million profit in Q3 1994, primarily due to the absence of $78 million in restructuring charges recorded in the prior year. The Chemicals segment saw operating earnings rise from $27 million to $68 million.
- Divestiture Charges: A $85 million charge was recorded in the first nine months of 1994 related to the divestiture of the Biomedical Systems Division, largely due to the reversal of an anticipated gain on the sale of its sensors business.
Guidance, Outlook, and Risks
- Management Commentary: Management attributes improved results to lower manufacturing costs, sales mix improvements, and higher prices. They note that inflation and unfavorable currency translation in Europe partially offset gains.
- Environmental Contingencies: The company maintains environmental reserves of $88 million. Management estimates that unrecorded environmental losses could range from $200 million to $400 million, though these are not currently considered probable. Resolution is expected over 20+ years.
- Capital Allocation: The Board approved a repurchase of 6.5 million shares of common stock. Dividends per share were $0.28 for the quarter and $0.83 for the nine-month period.
- Risks: Key risks include the uncertainty of final environmental remediation costs, foreign currency fluctuations, and the impact of inflation on commodity prices.
Investor Verification Checklist
- Accounting Changes: Verify the impact of the 1993 adoption of SFAS No. 106 (postretirement benefits) and SFAS No. 109 (income taxes) on year-over-year comparability.
- Biomedical Divestiture: Confirm the status of the remaining assets of the Biomedical Systems Division and the likelihood of future gains or losses on their disposal.
- Environmental Exposure: Review the specific details of the four sites contributing significantly to the unrecorded $200-$400 million environmental exposure.
- Stock Split Adjustments: Ensure all per-share data is adjusted for the 2-for-1 stock split effective June 10, 1994.
- Debt Structure: Analyze the reduction in short-term borrowings and the mix of fixed vs. variable rate debt given the company's interest rate risk management policies.